solithromycin (Solitaire)
Jump to navigation
Jump to search
Indications
- monotherapy for community-acquired pneumonia*
* non-inferior to moxifloxacin[1]
Dosage
- 800 mg on day 1, 400 mg on days 2-5
Adverse effects
More general terms
References
- ↑ 1.0 1.1 Barrera CM, Mykietiuk A, Metev H et al Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). Lancet Infectious Diseases. Feb 4, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26852726 <Internet> http://thelancet.com/journals/laninf/article/PIIS1473-3099%2816%2900017-7/abstract